Last updated: September 21, 2026
Vismodegib, marketed as Erivedge by Roche’s Genentech, is a targeted Hedgehog-pathway inhibitor approved for adults with advanced basal cell carcinoma (BCC). Its commercial profile is mature rather than growth-oriented: revenue has remained in the several-hundred-million Swiss franc range, supported by a narrow but durable oncology indication, while long-term growth is constrained by safety-related treatment discontinuation, a limited addressable population, and competition from surgery, radiation, and newer Hedgehog-pathway therapy.
Roche’s reported Erivedge sales declined from roughly CHF 430 million in 2019 to approximately CHF 380 million in 2023. The product remains commercially relevant, but its financial trajectory is more consistent with a stable specialty oncology franchise than with a high-growth asset. Core risks are patent expiry, generic entry, treatment intolerance, and the limited expansion of its label.
What is vismodegib and how does Erivedge generate revenue?
Vismodegib is an orally administered small-molecule inhibitor of Smoothened, a transmembrane protein in the Hedgehog signaling pathway. Aberrant Hedgehog signaling is implicated in the development of most BCC cases associated with basal-cell nevus syndrome and a subset of advanced sporadic BCC.
The FDA approved Erivedge in January 2012 for adults with metastatic BCC or locally advanced BCC that has recurred following surgery or who are not candidates for surgery or radiation therapy.[1] The approved indication is narrow and positions vismodegib after conventional local treatment options.
| Product attribute |
Detail |
| Active ingredient |
Vismodegib |
| Brand |
Erivedge |
| Original developer |
Genentech, Roche |
| Drug class |
Hedgehog-pathway inhibitor |
| Administration |
Oral capsule |
| Standard dose |
150 mg once daily |
| Initial FDA approval |
January 30, 2012 |
| Primary indication |
Metastatic or locally advanced BCC |
| Main commercial markets |
United States, Europe, Japan and other major markets |
| Principal competitors |
Sonidegib, surgery, radiation and investigational Hedgehog-pathway approaches |
The product’s revenue base depends on chronic or repeated treatment in patients with advanced disease. In practice, treatment duration is often limited by muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea and other adverse events. These tolerability issues reduce persistence and constrain revenue per patient.
What is the financial trajectory of Erivedge?
Erivedge has generated durable but declining sales for Roche. The product reached commercial maturity several years after launch, and reported revenue has generally trended downward from its earlier peak.
| Fiscal year |
Approximate Roche-reported Erivedge sales |
Commercial interpretation |
| 2019 |
CHF 430 million |
Mature specialty-oncology product |
| 2020 |
CHF 400 million |
Resilient demand despite pandemic disruption |
| 2021 |
CHF 400 million |
Broadly stable revenue |
| 2022 |
CHF 400 million |
Flat-to-declining mature franchise |
| 2023 |
CHF 380 million |
Continued erosion in established markets |
Sources: Roche annual reports for 2019 through 2023.[2-6]
Roche reports product sales in Swiss francs, so changes in reported revenue reflect both underlying demand and currency translation. The approximate 2019-2023 decline represents a low-single-digit annual erosion rate before adjusting for exchange-rate effects.
What explains the decline in vismodegib revenue?
Four factors shape Erivedge’s financial trajectory:
-
A limited eligible population. Advanced BCC is clinically important but represents a small portion of total BCC cases. Most BCC patients are treated successfully with local surgery, curettage, Mohs surgery or radiation.
-
Treatment discontinuation. Vismodegib’s adverse-event burden is commercially important. In the pivotal ERIVANCE BCC study, muscle spasms, alopecia, dysgeusia, weight loss and fatigue were frequent treatment-related events.[1]
-
Intermittent use and treatment holidays. Patients may stop and restart treatment because of toxicity or disease management decisions. This reduces the duration of continuous drug exposure.
-
Mature-market erosion. The product has been available for more than a decade. New patient growth is insufficient to offset discontinuations, treatment switching and eventual generic competition.
What is the current market position of vismodegib?
Vismodegib occupies a specialized position in advanced BCC. Its strongest commercial use is in patients whose disease is unresectable, metastatic or unsuitable for radiation. It is not a broad first-line treatment for ordinary BCC.
How large is the addressable market?
The addressable market consists of:
- Patients with locally advanced BCC that cannot be treated adequately with surgery or radiation.
- Patients with metastatic BCC.
- Patients with extensive, recurrent or anatomically difficult disease.
- Patients with basal-cell nevus syndrome who develop multiple difficult-to-manage tumors.
The market is geographically concentrated in developed healthcare systems with access to dermatologic oncology, medical oncology and specialty pharmacy distribution. United States demand is supported by the drug’s FDA approval and reimbursement infrastructure. European demand depends on national reimbursement decisions and local treatment pathways.
How does vismodegib compare with sonidegib?
Sonidegib, marketed as Odomzo by Sun Pharmaceutical Industries, is the principal approved systemic competitor in the same therapeutic class. Both drugs inhibit Smoothened and target advanced BCC.
| Factor |
Vismodegib |
Sonidegib |
| Brand |
Erivedge |
Odomzo |
| Developer |
Genentech/Roche |
Novartis; commercialized by Sun Pharma in key markets |
| Target |
Smoothened |
Smoothened |
| FDA approval |
2012 |
2015 |
| Indication |
Advanced BCC |
Locally advanced BCC after surgery or radiation are inappropriate |
| Dosing |
150 mg once daily |
200 mg once daily |
| Commercial position |
Established class leader |
Smaller challenger |
| Key barriers |
Tolerability, treatment persistence, patent expiry |
Smaller commercial base and class-level tolerability limitations |
Vismodegib benefits from earlier market entry, greater clinical familiarity and a broader historical commercial footprint. Sonidegib competes on physician preference, patient-specific tolerability and payer positioning rather than on a materially different mechanism.
What FDA regulatory status does vismodegib have?
The FDA approved vismodegib through the standard new drug application pathway, with priority review and an accelerated development history reflecting the unmet need in advanced BCC. The product is approved for adults and carries major reproductive safety restrictions because Hedgehog-pathway inhibition can cause embryo-fetal harm.
The label includes requirements relating to pregnancy testing, contraception and blood donation. Vismodegib has a long terminal half-life, which increases the practical importance of post-treatment reproductive precautions.[1]
The FDA label does not establish vismodegib as a treatment for ordinary, surgically manageable BCC. Its commercial value depends on the severe end of the disease spectrum.
Does vismodegib have orphan-drug protection?
Vismodegib’s advanced BCC indication was developed in an orphan-disease context, but orphan exclusivity is separate from patent protection. Any orphan exclusivity associated with the original approval does not replace the need to evaluate the patent estate, pediatric exclusivity, regulatory exclusivity and Orange Book listings.
For a mature product approved in 2012, current commercial protection depends primarily on remaining patents and the timing of ANDA litigation rather than on the original regulatory exclusivity period.
What patents protect Erivedge and when does vismodegib lose exclusivity?
The principal U.S. protection for vismodegib has historically come from composition-of-matter and related patent rights covering the active molecule and pharmaceutical compositions. Public patent databases identify Roche and Genentech patent families associated with vismodegib, including U.S. patents in the 7.8 million and 8.6 million series.
Because expiration dates can change with patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers and Orange Book listing practice, the operative date must be taken from the current FDA Orange Book and the relevant USPTO records.
| Protection category |
Commercial relevance |
| Composition of matter |
Primary barrier to early generic substitution |
| Pharmaceutical composition |
May protect dosage-form or formulation combinations |
| Method of treatment |
Can support litigation where the generic label induces infringement |
| Regulatory exclusivity |
Historically important but largely exhausted for a 2012 approval |
| Pediatric extension |
May extend selected patent rights if granted and applicable |
| Orange Book listing |
Determines the patents that an ANDA applicant must address |
What is the Orange Book status of Erivedge?
Erivedge is an FDA-approved drug subject to Orange Book patent-listing rules. The listed patents determine whether an ANDA applicant must submit a Paragraph I, II, III or IV certification.
A Paragraph IV certification alleges that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic. If the innovator sues within the statutory period, FDA approval may be subject to a 30-month stay, unless the litigation is resolved earlier or the stay is otherwise altered.
The commercial significance of any listed Erivedge patent depends on whether the patent covers the active ingredient, the approved 150 mg capsule, or only a narrower formulation or method of use.
Which companies are challenging vismodegib exclusivity?
No broad, high-profile generic challenge has established a major U.S. market event comparable to the challenges involving large cardiovascular, diabetes or immunology products. Generic entry remains a timing risk because oral small-molecule products are technically easier to copy than biologics, and the indication can often be addressed through a label that avoids some method-of-use claims.
Potential entrants include large generic companies and specialty generic manufacturers with oncology distribution capabilities. The likely entry strategy would involve an ANDA for a 150 mg capsule, coupled with patent certifications against any remaining listed patents.
The main litigation questions would be:
- Whether the composition-of-matter patent remains enforceable.
- Whether the generic applicant can establish non-infringement or invalidity.
- Whether method-of-use claims cover the proposed label.
- Whether formulation claims are broad enough to reach a conventional generic capsule.
- Whether a settlement permits a licensed or authorized generic launch.
What generic launch scenarios exist for vismodegib?
Three scenarios are commercially plausible.
Scenario 1: Delayed generic entry
A composition patent or enforceable Orange Book-listed patent blocks approval until the relevant expiration date. Erivedge retains branded pricing, although net price may decline through contracting and payer pressure.
Scenario 2: Patent settlement with an agreed entry date
Roche and an ANDA applicant settle Paragraph IV litigation. The agreement may establish a future generic launch date, an authorized generic arrangement or other commercial terms. The value of the settlement depends on the remaining patent term and whether multiple applicants receive the same entry rights.
Scenario 3: At-risk or early generic launch
A generic company launches after obtaining approval or after prevailing in patent litigation. Specialty oncology products can experience rapid price erosion, although the rate depends on the number of entrants, channel concentration and physician willingness to substitute.
For an oral oncology drug with a narrow patient population, the first generic entrant may capture meaningful volume, but total generic revenue can remain modest because the market itself is limited.
How strong is the vismodegib patent estate?
The estate is strongest where it relies on a valid composition-of-matter patent with a remaining enforceable term. It is weaker when protection depends on narrow formulation claims or treatment-method claims that can be avoided through generic labeling.
| Patent-estate factor |
Assessment |
| Molecule complexity |
Moderate; vismodegib is a defined small molecule |
| Generic manufacturing difficulty |
Moderate, not biologic-level |
| Formulation barrier |
Likely limited for a conventional capsule |
| Clinical differentiation |
Limited because sonidegib shares the same target |
| Label-based protection |
Potentially meaningful but dependent on claim scope |
| Litigation exposure |
Increases as remaining patent term shortens |
| Substitution risk |
High after multiple generic approvals |
Manufacturing does not appear to present the type of barrier associated with complex biologics, sterile injectables or individualized cell therapies. The principal barrier is legal protection, not manufacturing know-how.
What formulation patents protect vismodegib?
Vismodegib is marketed as an oral capsule. Formulation protection may cover specific excipients, capsule compositions, solid-state properties or processes, but a formulation patent has less strategic value than a broad composition patent if a generic can develop a non-infringing formulation with equivalent bioavailability.
For a standard oral capsule, generic substitution risk generally rises once the core active-ingredient patent expires. A narrow formulation patent can delay some applicants, but it is less likely to preserve long-term exclusivity across the entire market.
What method-of-use patents protect Erivedge?
Method-of-use patents may cover treatment of advanced BCC, Hedgehog-pathway-driven tumors, basal-cell nevus syndrome or specific patient populations. Their enforceability depends on claim language and the generic product label.
A generic applicant may attempt a skinny label that omits patented uses. That strategy reduces the practical reach of method-of-use patents when the remaining unpatented indications support approval. Conversely, a product with only one meaningful approved use is more exposed to induced-infringement arguments if the generic label necessarily directs use for the patented indication.
What litigation and settlement risks affect Erivedge?
The principal litigation risk is an ANDA Paragraph IV case in federal district court. The outcome would affect:
- FDA approval timing.
- The 30-month stay.
- The possibility of an earlier generic launch.
- The value of remaining Roche sales.
- Any licensing or authorized-generic economics.
Publicly visible litigation activity around Erivedge has not produced a widely reported, market-defining settlement comparable to major blockbuster drug cases. This does not eliminate Paragraph IV risk. It indicates that the product’s commercial scale and remaining patent life may make future disputes more economically contained than litigation involving billion-dollar products.
Does vismodegib face biosimilar risk?
No. Vismodegib is a chemically synthesized small molecule, not a biologic. It is exposed to generic-drug competition through the ANDA pathway rather than biosimilar competition under the Biologics Price Competition and Innovation Act.
The practical distinction is significant. Generic competitors do not need to reproduce a biologic manufacturing process or demonstrate biosimilarity. They generally rely on pharmaceutical equivalence and bioequivalence, subject to FDA requirements.
What licensing deals affect vismodegib?
Genentech developed and commercialized Erivedge within the Roche group. The key commercial relationship is therefore internal to Roche rather than a prominent external license involving a separate global pharmaceutical company.
The Hedgehog inhibitor field includes external research collaborations and licensing transactions involving other molecules, but those deals do not automatically create rights to vismodegib or reduce Roche’s ownership of Erivedge. Any assessment of a third-party license must distinguish platform-level Hedgehog rights from product-specific vismodegib rights.
What is the revenue exposure to Roche from Erivedge?
Erivedge represents a small share of Roche’s total pharmaceutical revenue. Roche’s group sales are measured in tens of billions of Swiss francs, while Erivedge sales are measured in hundreds of millions. The product is therefore not financially transformative for Roche.
Its strategic value is higher than its group revenue share suggests because it provides:
- A commercial presence in advanced BCC.
- A mature oncology product with established physician familiarity.
- A platform for clinical experience with Hedgehog-pathway inhibition.
- Specialty-pharmacy and oncology-channel relationships.
A generic launch would have limited effect on Roche’s total corporate revenue but could materially reduce the product’s contribution margin and remaining franchise value.
How does vismodegib compare with other Roche oncology products?
Erivedge is materially smaller than Roche’s leading oncology products, including Tecentriq, Perjeta, Kadcyla, Herceptin and Alecensa. Those products address larger patient populations or higher-value treatment settings.
| Product |
Roche position |
Relative commercial scale |
| Erivedge |
Mature targeted therapy for advanced BCC |
Small specialty franchise |
| Tecentriq |
Immuno-oncology therapy |
Larger and broader market |
| Perjeta |
HER2-targeted therapy |
Major oncology franchise |
| Kadcyla |
Antibody-drug conjugate |
Larger, biologically complex product |
| Alecensa |
ALK-targeted therapy |
Larger molecularly defined market |
Erivedge’s lower revenue base reduces corporate exposure but also limits Roche’s incentive to pursue extensive lifecycle investment unless a new indication offers a credible return.
What is the outlook for vismodegib through generic entry?
The base case is stable-to-declining revenue before generic entry, followed by accelerated erosion once an approved generic reaches the market. The timing of that transition depends on the operative Orange Book patent estate and any Paragraph IV settlement.
Commercial performance will remain dependent on:
- The number of patients unsuitable for local therapy.
- Treatment persistence and management of adverse events.
- Physician preference between vismodegib and sonidegib.
- Reimbursement for specialty oral oncology products.
- The ability of Roche to maintain pricing and patient-support programs.
- The timing and number of generic entrants.
The product’s strongest defense is clinical familiarity in a rare treatment setting. Its principal weakness is that it is a conventional oral small molecule with a narrow label and substantial tolerability limitations.
Key Takeaways
- Vismodegib is Roche’s Erivedge, an oral Smoothened inhibitor approved for advanced basal cell carcinoma.
- Roche sales declined from about CHF 430 million in 2019 to approximately CHF 380 million in 2023.
- The product is commercially mature and has limited growth potential without meaningful label expansion.
- Revenue is constrained by the small advanced-BCC population and high treatment discontinuation caused by adverse events.
- Sonidegib is the principal branded competitor, but local surgery and radiation remain the main alternatives.
- Vismodegib is exposed to generic, not biosimilar, competition.
- The central exclusivity question is the remaining term and enforceability of Roche’s listed composition, formulation and method-of-use patents.
- A Paragraph IV challenge could create a 30-month FDA approval stay if Roche files timely litigation.
- Generic entry would likely produce rapid price erosion, with the first entrant obtaining the strongest commercial position.
- Erivedge is strategically useful but represents a limited share of Roche’s overall revenue.
FAQs
Is vismodegib still commercially important to Roche?
Yes, but it is a mature specialty product rather than a major Roche growth driver. Annual sales remain in the hundreds of millions of Swiss francs, while Roche’s total pharmaceutical revenue is many times larger.
Can patients take vismodegib long term?
Some patients receive prolonged treatment, but long-term use is often limited by adverse events such as muscle spasms, alopecia, dysgeusia and weight loss. Treatment interruptions and discontinuations affect revenue per patient.
Is Erivedge interchangeable with Odomzo?
No. Both drugs inhibit Smoothened, but they are separate products with different clinical-development histories, labels, dosing considerations and regulatory approvals. Substitution requires clinical and regulatory judgment.
Will a vismodegib generic automatically replace Erivedge?
An FDA-approved generic may be substitutable under applicable state and federal pharmacy rules, but actual substitution will depend on FDA therapeutic-equivalence ratings, payer policies, contracts, physician prescribing and specialty-pharmacy distribution.
Does Roche have a biosimilar problem with Erivedge?
No. Erivedge is a small-molecule drug. The relevant threat is an ANDA-approved generic, not a biosimilar.
References
- U.S. Food and Drug Administration. (2023). Erivedge (vismodegib) prescribing information.
- Roche Holding AG. (2020). Annual report 2019.
- Roche Holding AG. (2021). Annual report 2020.
- Roche Holding AG. (2022). Annual report 2021.
- Roche Holding AG. (2023). Annual report 2022.
- Roche Holding AG. (2024). Annual report 2023.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2012). FDA approves Erivedge for advanced basal cell carcinoma.
